



PERSONALIZING CANCER MEDICINE IN 2015

February 2 - 3, 2015 | Hyatt Regency, Toronto, Canada

PROGRAM AGENDA - FEBRUARY 3

Time	Program Title
8:00 - 8:50	Breakfast and Registration (King Ballroom Foyer)
8:50 - 9:00	Welcome and Introduction (King Ballroom) Lillian Siu
9:00 - 9:45	Opening Keynote Speaker A Translational Pathway for Pain and Symptom Treatment in Oncology Charles Cleeland
9:45 - 10:00	Question and Answer Period
10:00 - 10:30	Morning Break
10:30 - 12:30	Supportive Care Chair: Madeline Li Moderator: Gary Rodin 10:30 - 11:00 <ul style="list-style-type: none">Plenary Keynote Speaker Cognitive Functioning in Cancer Patients with Non-Central Nervous System Disease Sanne Schagen 11:00 - 11:20 <ul style="list-style-type: none">The Priorities for Cancer Survivorship Jennifer Jones 11:20 - 11:40 <ul style="list-style-type: none">The Distress Assessment and Response Tool (DART) at Princess Margaret: Making Personalized Medicine More Personal Madeline Li 11:40 - 12:30 <ul style="list-style-type: none">Case-based Panel Discussion Moderator: Gary Rodin Panelists: Charles Cleeland, Sanne Schagen, Madeline Li, Jennifer Jones
12:30 - 1:30	Lunch and Poster Viewing Session
1:30 - 2:00	Poster Discussion Session - Clinical Posters Facilitators: Kim N. Chi, Julia Ridley

PROGRAM AGENDA - FEBRUARY 3

Time	Program Title
2:00 - 3:50	<p>Genomics</p> <p>Chair: Tracy Stockley Moderator: Philippe Bedard</p> <p>2:00 - 2:30</p> <ul style="list-style-type: none">• Plenary Keynote Speaker Next-Generation Sequencing in Oncology Practice: Progress and Challenges Allison Kurian <p>2:30 - 2:50</p> <ul style="list-style-type: none">• Diagnostic Genomics for Oncology Tracy Stockley <p>2:50 - 3:10</p> <ul style="list-style-type: none">• Personalizing Ovarian Cancer Treatment Through Synthetic Lethality Amit Oza <p>3:10 - 3:50</p> <ul style="list-style-type: none">• Case-based Panel Discussion Co-Moderators: Philippe Bedard, Tracy Stockley Panelists: Allison Kurian, Amit Oza, Raymond Kim, Jeanna McCuaig
3:50 - 4:50	<p>Debate</p> <p>“This house believes that immunotherapy will double cancer-specific survival, compared to molecular targeted therapies, in the next 10 years”</p> <p>Moderator: Robert Bristow</p> <p>For: Tak W. Mak, Marcus Butler Against: Kim N. Chi, Philippe Bedard</p>
4:50	<p>Closing Remarks</p> <p>Peter Pisters</p>